Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines

Simron Singh; Emily K Bergsland; Cynthia M Card; Thomas A Hope; Pamela L Kunz; David T Laidley; Ben Lawrence; Simone Leyden; David C Metz; Michael Michael; Lucy E Modahl; Sten Myrehaug; Sukhmani K Padda; Rodney F Pommier; Robert A Ramirez; Michael Soulen; Jonathan Strosberg; Arthur Sung; Alia Thawer; Benjamin Wei; Bin Xu; Eva Segelov

doi:10.1016/j.jtho.2020.06.021

Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines

J Thorac Oncol. 2020 Oct;15(10):1577-1598. doi: 10.1016/j.jtho.2020.06.021. Epub 2020 Jul 11.

Authors

Simron Singh¹, Emily K Bergsland², Cynthia M Card³, Thomas A Hope⁴, Pamela L Kunz⁵, David T Laidley⁶, Ben Lawrence⁷, Simone Leyden⁸, David C Metz⁹, Michael Michael¹⁰, Lucy E Modahl¹¹, Sten Myrehaug¹², Sukhmani K Padda¹³, Rodney F Pommier¹⁴, Robert A Ramirez¹⁵, Michael Soulen¹⁶, Jonathan Strosberg¹⁷, Arthur Sung¹⁸, Alia Thawer¹², Benjamin Wei¹⁹, Bin Xu¹², Eva Segelov²⁰

Affiliations

¹ Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address: [email protected].
² Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California.
³ Tom Baker Cancer Centre, Calgary, Alberta, Canada.
⁴ Department of Radiology and Biomedical Imaging, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California.
⁵ Department of Medicine, Yale University, New Haven, Connecticut.
⁶ Department of Medical Imaging, Division of Nuclear Medicine, London Health Sciences Centre, London, Ontario, Canada.
⁷ Discipline of Oncology, University of Auckland, Auckland, New Zealand.
⁸ Unicorn Foundation, Blairgowrie, Victoria, Australia.
⁹ Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
¹⁰ Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
¹¹ Auckland Radiology Group, Auckland City Hospital, Auckland, New Zealand.
¹² Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
¹³ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
¹⁴ Oregon Health & Science University, Portland, Oregon.
¹⁵ Department of Medical Oncology, Ochsner Medical Center, New Orleans, Louisiana.
¹⁶ Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
¹⁷ Moffitt Cancer Center, Tampa, Florida.
¹⁸ Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, California.
¹⁹ Department of Surgery, Birmingham Medical Center, University of Alabama, Birmingham, Alabama.
²⁰ Department of Oncology, Monash Health, Monash University, Melbourne, Victoria, Australia.

PMID: 32663527
DOI: 10.1016/j.jtho.2020.06.021

Abstract

Lung neuroendocrine tumors (LNETs) are uncommon cancers, and there is a paucity of randomized evidence to guide practice. As a result, current guidelines from different neuroendocrine tumor societies vary considerably. There is a need to update and harmonize global consensus guidelines. This article reports the best practice guidelines produced by a collaboration between the Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society. We performed a formal endorsement and updating process of the 2015 European Neuroendocrine Tumor Society expert consensus article on LNET. A systematic review from January 2013 to October 2017 was conducted to procure the most recent evidence. The stepwise endorsement process involved experts from all major subspecialties, patients, and advocates. Guided by discussion of the most recent evidence, each statement from the European Neuroendocrine Tumor Society was either endorsed, modified, or removed. New consensus statements were added if appropriate. The search yielded 1109 new publications, of which 230 met the inclusion criteria. A total of 12 statements were endorsed, 22 statements were modified or updated, one was removed, and two were added. Critical answered questions for each topic in LNET were identified. Through the consensus process, guidelines for the management of patients with local and metastatic neuroendocrine tumors have been updated to include both recent evidence and practice changes relating to technological and definitional advances. The guidelines provide clear, evidence-based statements aimed at harmonizing the global approach to patients with LNETs, on the basis of the principles of person-centered and LNET-specific care. The importance of LNET-directed research and person-centered care throughout the diagnosis, treatment, and follow-up journey is emphasized along with directions for future collaborative research.

Keywords: Bronchial neuroendocrine tumors/tumours; Consensus statements; Guidelines; Lung carcinoids; Lung neuroendocrine tumors/tumours.

Publication types

Review
Systematic Review

MeSH terms

Carcinoma, Neuroendocrine*
Consensus
Humans
Lung
Lung Neoplasms* / diagnosis
Lung Neoplasms* / therapy
Neuroendocrine Tumors* / diagnosis
Neuroendocrine Tumors* / therapy
United States